Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
This RFP seeks development of small-molecule antifungal compounds effective against resistant fungi like Candida auris and Aspergillus species. The goal is to address rising fungal infection rates and hospitalizations by creating safer, broad-spectrum alternatives to current treatments limited by toxicity and drug resistance.